
    
      The primary objective of this study is to evaluate the intermediate/long-term safety of
      inhaled nebulized AIR001 administered according to 3 treatment arms (80 milligrams (mg) 4
      times daily, 46 mg 4 times daily, or 80 mg once daily) in subjects with World Health
      Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH) who have completed the
      16-week AIR001-CS05 study.
    
  